Publications by authors named "Jan Rosing"

Claim this Profile
S
Severe thrombophilia in a factor V-deficient patient homozygous for the Ala2086Asp mutation (FV Besançon).
Elisabetta Castoldi, Nathalie Hézard, Guillaume Mourey, Kanin Wichapong, Marjorie Poggi, Jan Rosing

J Thromb Haemost· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters.
Jonathan Douxfils, Christine Klipping, Ingrid Duijkers, Virginie Kinet, Marie Mawet, Jan Rosing

Contraception· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Plasma-Based Assay to Measure the Susceptibility of Factor V to Inhibition by the C-Terminus of TFPIα.
Peter van Doorn, Jan Rosing, Elena Campello, Saskia Middeldorp, Paolo Simioni

Thromb Haemost· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factor V Has Anticoagulant Activity in Plasma in the Presence of TFPIα: Difference between FV1 and FV2.
Peter van Doorn, Jan Rosing, Connie Duckers, Tilman M Hackeng, Paolo Simioni

Thromb Haemost· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endogenous thrombin potential changes during the first cycle of oral contraceptive use.
Carolyn L Westhoff, Malcolm C Pike, Serge Cremers, Andrew Eisenberger, Stella Thomassen, Jan Rosing

Contraception· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women.
Laura B Harrington, Marc Blondon, Mary Cushman, Andrew M Kaunitz, Jacques E Rossouw, Jan Rosing

Menopause· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of exosite binding modulators in the inhibition of Fxa by TFPI.
Sameera Peraramelli, Stella Thomassen, Alexandra Heinzmann, Tilman M Hackeng, Rudolf Hartmann, Jan Rosing

Thromb Haemost· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy.
Karen C Johnson, Aaron K Aragaki, Rebecca Jackson, Alex Reiner, Per Morten Sandset, Jan Rosing

Arterioscler Thromb Vasc Biol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fibrinogen γ' increases the sensitivity to activated protein C in normal and factor V Leiden plasma.
Farida Omarova, Shirley Uitte de Willige, Paolo Simioni, Robert A S Ariëns, Rogier M Bertina, Jan Rosing

Blood· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI).
Michael Dockal, Rudolf Hartmann, Markus Fries, M Christella L G D Thomassen, Alexandra Heinzmann, Jan Rosing

J Biol Chem· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obesity and thrombin-generation profiles in women with venous thromboembolism.
Kristina Sonnevi, Svetlana N Tchaikovski, Margareta Holmström, Jovan P Antovic, Katarina Bremme, Jan Rosing

Blood Coagul Fibrinolysis· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI.
Marjolein Raps, Frans M Helmerhorst, Kathrin Fleischer, Anders E A Dahm, Frits R Rosendaal, Jan Rosing

Thromb Haemost· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa.
Sameera Peraramelli, Dennis P L Suylen, Jan Rosing, Tilman M Hackeng

Thromb Haemost· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TFPI-dependent activities of protein S.
Sameera Peraramelli, Jan Rosing, Tilman M Hackeng

Thromb Res· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy.
Jacques E Rossouw, Karen C Johnson, Mary Pettinger, Mary Cushman, Per Morten Sandset, Jan Rosing

Stroke· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Active site-labeled prothrombin inhibits prothrombinase in vitro and thrombosis in vivo.
Heather K Kroh, Peter Panizzi, Svetlana Tchaikovski, T Regan Baird, Nancy Wei, Jan Rosing

J Biol Chem· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombin generation tests.
Elisabetta Castoldi, Jan Rosing

Thromb Res· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency.
Elisabetta Castoldi, Lisbeth F A Maurissen, Daniela Tormene, Luca Spiezia, Sabrina Gavasso, Jan Rosing

Haematologica· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of estrogen-induced venous thromboembolism.
Svetlana N Tchaikovski, Jan Rosing

Thromb Res· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of thrombin formation by active site mutated (S360A) activated protein C.
Gerry A F Nicolaes, Paul E Bock, Kenneth Segers, Karin C A A Wildhagen, Björn Dahlbäck, Jan Rosing

J Biol Chem· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from mixed type I/III families.
Elisabetta Castoldi, Lisbeth F A Maurissen, Daniela Tormene, Luca Spiezia, Sabrina Gavasso, Jan Rosing

Haematologica· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms.
Connie Duckers, Paolo Simioni, Luca Spiezia, Claudia Radu, Paolo Dabrilli, Jan Rosing

Blood· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the contraceptive vaginal ring, the contraceptive transdermal patch and combined oral contraceptives on markers of hemostasis.
Huib A A M van Vliet, Frits R Rosendaal, Kathrin Fleischer, Jan Rosing, Frans M Helmerhorst

Contraception· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombin generation as an intermediate phenotype for venous thrombosis.
Olivier Segers, René van van Oerle, Hugo ten ten Cate, Jan Rosing, Elisabetta Castoldi

Thromb Haemost· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein S as cofactor for TFPI.
Tilman M Hackeng, Jan Rosing

Arterioscler Thromb Vasc Biol· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis